Drug Profile

OMS 1620

Alternative Names: MC2 antagonist therapeutic - OMass Therapeutics; OMS-1620

Latest Information Update: 15 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator OMass Therapeutics
Class Small molecules
Mechanism of Action Melanocortin type 2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Congenital adrenal hyperplasia; Cushing syndrome

Most Recent Events

09 Sep 2026 OMass Therapeutics plans a phase I trial for Congenital adrenal hyperplasia (In volunteers, In adults) in an unknown country (PO), in September 2026 , (NCT07811089)
28 Jan 2026 OMass Therapeutics plans clinical trial for unspecified indicaton
14 Jul 2025 Pharmacodynamics data from a preclinical study in Congenital adrenal hyperplasia released by OMass Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com